Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm.

Figure1 PANSS responders (defined by PANSS total score reduction thresholds of 20-50%) with AL 441 mg, 882 mg, or AL doses pooled: NNTand 95% CI vs placebo, at Placebo (n=196) AL 441 mg q4wk (n=196) AL 882 mg q4wk (n=204) AL Pooled (n=400) Placebo (n=207) AL 441 mg q4wk (n=207) AL 882 mg q4wk (n=208) AL Pooled (n=415) Placebo (n=207) AL 441 mg q4wk (n=207) AL 882 mg q4wk (n=208) AL Pooled (n=415). [Extracted from the article]